![Yao Chang Xu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Yao Chang Xu
Directeur Général chez
ABBISKO CAYMAN LIMITED
Fortune : 104 M $ au 31/07/2026
Profil
Dr. Yao Chang Xu is a Chairman & Chief Executive Officer at Abbisko Cayman Ltd. and a Chairman & Chief Executive Officer at Abbisko Therapeutics Co., Ltd. He is on the Board of Directors at Abbisko Therapeutics Australia Pty Ltd., Wuxi Abbisko Biomedical Technology Co. Ltd. and Abbisko Hong Kong Ltd. Dr. Xu was previously employed as a General Manager by Hansoh Pharmaceutical Group Co., Ltd., a General Manager by Shanghai Hansoh Biomedical Co. Ltd., an Executive Director by Novartis International AG, and a Head-Discovery Chemistry by Eli Lilly & Co. He received his undergraduate degree from Nanjing University and a doctorate degree from The University of Chicago.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ABBISKO CAYMAN LIMITED 11,17% | 28/04/2026 | 81 099 968 ( 11,17% ) | 104 M $ | 31/07/2026 |
Postes actifs de Yao Chang Xu
| Sociétés | Poste | Début |
|---|---|---|
| ABBISKO CAYMAN LIMITED | Directeur Général | 28/03/2018 |
Abbisko Therapeutics Co., Ltd.
 Abbisko Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology Researches and develops biomedicine and biotechnology | Directeur Général | 12/04/2016 |
Abbisko Hong Kong Ltd. | Directeur/Membre du Conseil | 01/04/2018 |
Wuxi Abbisko Biomedical Technology Co. Ltd. | Directeur/Membre du Conseil | 01/07/2020 |
Abbisko Therapeutics Australia Pty Ltd. | Directeur/Membre du Conseil | 01/12/2020 |
Anciens postes connus de Yao Chang Xu
| Sociétés | Poste | Fin |
|---|---|---|
| HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED | Corporate Officer/Principal | 01/03/2016 |
Shanghai Hansoh Biomedical Co. Ltd. | Corporate Officer/Principal | 01/03/2016 |
Novartis International AG
 Novartis International AG Pharmaceuticals: MajorHealth Technology Offers healthcare solutions | Directeur/Membre du Conseil | 01/03/2012 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/01/2006 |
Formation de Yao Chang Xu
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
83
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Eli Lilly & Co.
 Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Offers healthcare solutions | Health Technology |
The University of Chicago
 The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nanjing University
 Nanjing University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Abbisko Therapeutics Co., Ltd.
Abbisko Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology Researches and develops biomedicine and biotechnology | Health Technology |
Hansoh Pharmaceutical Group Co., Ltd.
 Hansoh Pharmaceutical Group Co., Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and sells & develops pharmaceutical products | Health Technology |
Abbisko Cayman Ltd.
 Abbisko Cayman Ltd. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company dedicated to the discovery and development of small molecule oncology therapies | Health Technology |
Shanghai Hansoh Biomedical Co. Ltd. | |
Abbisko Hong Kong Ltd. | |
Wuxi Abbisko Biomedical Technology Co. Ltd. | |
Abbisko Therapeutics Australia Pty Ltd. |
